Patent application number | Description | Published |
20090192191 | Substituted hydroxamic acid derivatives as tnf inhibitors - The present invention relates to novel compounds of formula (I) and their pharmaceutically useful compositions as MMP and TNF inhibitors. | 07-30-2009 |
20100240709 | Sulfoximine Derivatives as p38 MAP Kinase Inhibitors - The present invention relates to novel compounds of general formula (I), their regioisomers, tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (I), their regioisomers, their tautomeric forms, their pharmaceutically acceptable salts pharmaceutical compositions containing them, and novel intermediates involved in their synthesis. | 09-23-2010 |
20120021972 | PEPTIDOMIMETICS WITH GLUCAGON ANTAGONISTIC AND GLP 1 AGONISTIC ACTIVITIES - The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-I receptor agonistic activity. | 01-26-2012 |
20120028996 | NOVEL OXIME DERIVATIVES - The present invention relates to novel oxime derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 02-02-2012 |
20120115907 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN - The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to a process of preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis. | 05-10-2012 |
20120252796 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES - The present invention relates to compounds of the general formula (I), | 10-04-2012 |
20120264685 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST - The present invention provides novel short chain peptidomimetics, which act as GLP-1 receptors agonist and glucagon receptor antagonist. These dual acting peptidomimetics exhibit increased stability to proteolytic cleavage, especially against DPP-IV (Dipeptidyl peptidase-IV) enzyme, GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro). Due to increased metabolic stability, other than parenteral route of administration, these short chain peptidomimetics can be delivered by oral routes of administration, for the treatment or prevention of diabetes and related metabolic disorders, such as obesity, hyperlipidemia and eating disorders. | 10-18-2012 |
20130203668 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIPLATELET AGENTS AND AN ERYTHROPOIESIS STIMULATING AGENT - A composition comprising suitable anti-platelet agent/agents and the erythropoiesis stimulating agent for the treatment and improvement of kidney function is described. The combination also provides treatment and improvement in cardiovascular and bleeding related disorders. This composition shows synergistic interaction and significantly reduces the kidney damage caused by administration of erythropoiesis stimulating agents. Moreover the present composition normalizes the platelet reactivity and bleeding time in patients with chronic kidney disease. | 08-08-2013 |
20130281366 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA - The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. | 10-24-2013 |